Pharvaris Showcases Deucrictibant Data at Recent Congresses

Pharvaris, a biopharmaceutical company based in Zug, Switzerland, has unveiled promising data on its novel drug, deucrictibant, designed to treat and prevent hereditary angioedema (HAE) attacks. The data was presented at major industry conferences including the 20th Annual Congress of International Drug Discovery Science and Technology (IDDST), the 2024 Eastern Allergy Conference (EAC), and the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2024.

Deucrictibant has shown significant effectiveness, with 78.6% of participants experiencing substantial symptom relief within 24 hours of an HAE attack. This high efficacy rate is accompanied by a favorable safety profile, making it a potentially preferred option for both on-demand and long-term prophylactic treatment of HAE. According to Peng Lu, M.D., Ph.D., Chief Medical Officer of Pharvaris, the drug's efficacy and convenience could set a new standard for HAE treatment.

Berndt Modig, CEO of Pharvaris, emphasized that the data supports deucrictibant's development as an oral treatment option for HAE, a condition historically managed with injectable therapies. The company aims to address the unmet needs of the HAE community by continuously evaluating real-world evidence and treatment behaviors.

The Phase 2 RAPIDe-1 clinical study further underscores deucrictibant's effectiveness. In this study, patients reported significant symptom relief within 24 hours of taking a single dose of the drug, as measured by the Treatment Outcome Score (TOS) questionnaire. Specifically, 78.6% of patients treated with 20 mg of deucrictibant achieved substantial symptom resolution, compared to just 22.4% in the placebo group.

In addition to these findings, Pharvaris is committed to exploring the broader potential of deucrictibant. The company is conducting long-term open-label extension studies to gather more data on the drug's safety and efficacy across various types of HAE attacks, including laryngeal episodes. Insights from these studies could further position deucrictibant as a leading treatment option for HAE.

Data from the Phase 2 CHAPTER-1 clinical study revealed high treatment satisfaction among participants, particularly concerning the drug's effectiveness. This was measured using the Treatment Satisfaction Questionnaire for Medication (TSQM). Deucrictibant's effectiveness score was notably higher than that of the placebo and aligned with high-efficacy injectable treatments. The global satisfaction score for deucrictibant was driven by high scores across all measured subdomains, including side effects and convenience.

Pharvaris remains dedicated to advancing the understanding of bradykinin-mediated diseases and exploring the potential applications of deucrictibant. The company is also focused on expanding its product portfolio to address additional indications, leveraging its expertise in rare diseases and HAE.

Deucrictibant works by antagonizing the bradykinin B2 receptor, thereby inhibiting bradykinin signaling. This mechanism helps treat and prevent the manifestations of HAE attacks. Pharvaris is developing two oral formulations of the drug: a capsule for rapid onset in acute treatment and an extended-release tablet for sustained efficacy in prophylactic use.

Pharvaris is a late-stage biopharmaceutical company specializing in novel, oral treatments for HAE. The company aims to provide safe, effective, and easy-to-administer alternatives for all HAE subtypes. Drawing on its deep expertise in rare diseases and HAE, Pharvaris continues to innovate and expand its therapeutic offerings to improve the lives of those affected by HAE.

In conclusion, the promising data on deucrictibant presented by Pharvaris highlights its potential as a groundbreaking treatment for HAE. With substantial symptom resolution observed in a majority of participants within 24 hours, deucrictibant stands out for its efficacy, safety, and convenience, making it a compelling option for both on-demand and prophylactic treatment of HAE.